Getting from genes to function in lung disease: a National Heart, Lung, and Blood Institute workshop report. Read more about Getting from genes to function in lung disease: a National Heart, Lung, and Blood Institute workshop report.
An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Read more about An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice.
Impact of the lung allocation score on lung transplantation for pulmonary arterial hypertension. Read more about Impact of the lung allocation score on lung transplantation for pulmonary arterial hypertension.
Ex vivo sputum analysis reveals impairment of protease-dependent mucus degradation by plasma proteins in acute asthma. Read more about Ex vivo sputum analysis reveals impairment of protease-dependent mucus degradation by plasma proteins in acute asthma.
Circulating endothelial microparticle levels predict hemodynamic severity of pulmonary hypertension. Read more about Circulating endothelial microparticle levels predict hemodynamic severity of pulmonary hypertension.
An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Read more about An essential role for fibronectin extra type III domain A in pulmonary fibrosis.
Disease-specific gene expression profiling in multiple models of lung disease. Read more about Disease-specific gene expression profiling in multiple models of lung disease.
Is giant cell interstitial pneumonitis synonymous with hard metal lung disease? Read more about Is giant cell interstitial pneumonitis synonymous with hard metal lung disease?
Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Read more about Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation.
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Read more about Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.
